Astrazeneca annual shares outstanding
2022
2023
2024
2025
Astrazeneca Shares Outstanding History (AZN)
Astrazeneca reported 1.55B shares outstanding at the end of fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.55B | 656,483 | +0.04% |
| 2024 | 2024-12-31 | 1.55B | −58,729 | −0.00% |
| 2023 | 2023-12-31 | 1.55B | 362,596 | +0.02% |
| 2022 | 2022-12-31 | 1.55B | — | — |
Astrazeneca quarterly shares outstanding
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.55B | 648,661 | +0.04% |
| Q1 2026 | 2026-03-31 | 1.55B | — | — |
| Q4 2025 | 2025-12-31 | 1.55B | — | — |
| Q3 2025 | 2025-09-30 | 1.55B | — | — |
| Q2 2025 | 2025-06-30 | 1.55B | — | — |
Astrazeneca shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Astrazeneca's shares outstanding moved from 1.55B to 1.55B, a change of 960,350. The latest reported quarter, Q2 2026, shows 1.55B.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...